Literature DB >> 2331573

Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?

M Pirovino1, U Honegger, O Müller, T Zysset, A Küpfer, M Tinel, D Pessayre.   

Abstract

1. It has previously been shown that the extent of hepatic phospholipidosis induced by chronic amiodarone treatment correlates with the degree of drug accumulation in liver tissue. 2. To investigate a possible influence of pharmacogenetic factors, biochemical and morphological investigations were carried out in two rat strains differing in debrisoquine hydroxylation. 3. Plasma and liver tissue concentrations of amiodarone and its main metabolite, desethyl-amiodarone, were significantly higher in rats with deficient hydroxylation. Microsomal enzyme induction, drug cytochrome P-450 complex formation and typical ultrastructural features of phospholipidosis were only seen in rats with deficient hydroxylation and in a more sensitive species, the guinea-pig. 4. It remains to be seen whether deficient debrisoquine hydroxylation in man is associated with an increased susceptibility to amiodarone side effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2331573      PMCID: PMC1917520          DOI: 10.1111/j.1476-5381.1990.tb14650.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

Review 1.  Inherited defects of hepatic drug metabolism.

Authors:  A Küpfer; R Preisig
Journal:  Semin Liver Dis       Date:  1983-11       Impact factor: 6.115

2.  Amiodarone hepatotoxicity simulating alcoholic liver disease.

Authors:  J B Simon; P N Manley; J F Brien; P W Armstrong
Journal:  N Engl J Med       Date:  1984-07-19       Impact factor: 91.245

3.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C.

Authors:  K Y Hostetler; Y Matsuzawa
Journal:  Biochem Pharmacol       Date:  1981-05-15       Impact factor: 5.858

5.  Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.

Authors:  S G Al-Dabbagh; J R Idle; R L Smith
Journal:  J Pharm Pharmacol       Date:  1981-03       Impact factor: 3.765

6.  Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies.

Authors:  S Poucell; J Ireton; P Valencia-Mayoral; E Downar; L Larratt; J Patterson; L Blendis; M J Phillips
Journal:  Gastroenterology       Date:  1984-05       Impact factor: 22.682

7.  Neuropathy and fatal hepatitis in a patient receiving amiodarone.

Authors:  P K Lim; P N Trewby; G C Storey; D W Hole
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-02

8.  The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone.

Authors:  M F Heath; F R Costa-Jussà; J M Jacobs; W Jacobson
Journal:  Br J Exp Pathol       Date:  1985-08

9.  Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.

Authors:  G Alván; M Grind; C Graffner; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875

10.  Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

Authors:  M Y Morgan; R Reshef; R R Shah; N S Oates; R L Smith; S Sherlock
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.